<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837730</url>
  </required_header>
  <id_info>
    <org_study_id>P/2018/353</org_study_id>
    <nct_id>NCT03837730</nct_id>
  </id_info>
  <brief_title>Citrulline and Arginase Activity in Severe Sepsis and Septic Shock</brief_title>
  <acronym>CARS</acronym>
  <official_title>Activity and Expression of Plasma Arginase in Patients With Severe Sepsis or Septic Shock as Prognostic Value</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is an acute pathology defined as an inappropriate response of the host to infection,&#xD;
      resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis&#xD;
      associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring&#xD;
      vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma&#xD;
      L-arginine deficiency. This deficiency induces a lower availability of L-arginine for&#xD;
      multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in&#xD;
      the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a&#xD;
      lower synthesis induces a vascular and endothelial dysfunction that can promote the&#xD;
      occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in&#xD;
      patients with sepsis and appears correlated with severity.&#xD;
&#xD;
      L-arginine deficiency can have multiple origins:&#xD;
&#xD;
        -  L-arginine deficiency resulting from a decrease in endogenous production from citrulline&#xD;
           synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in&#xD;
           patients with sepsis and is characterized biologically by elevated plasma levels of&#xD;
           I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis&#xD;
           marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity).&#xD;
&#xD;
        -  L-arginine deficiency may also result from a catabolism increase via arginase activity&#xD;
           increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the&#xD;
           synthesis of urea and ornithine from L-arginine. An increase in arginase activity would&#xD;
           decrease the available reserves of L-arginine for NO synthesis.&#xD;
&#xD;
      The objectives of this work is to evaluate, in patients with severe sepsis or septic shock,&#xD;
      the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms&#xD;
      Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and&#xD;
      enterocyte dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 10, 2019</start_date>
  <completion_date type="Anticipated">August 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prognostic value of plasma arginase activity and expression at ICU admission in patients with severe sepsis or septic shock</measure>
    <time_frame>28 days</time_frame>
    <description>activity / expression of plasma arginase at ICU admission and 28-day mortality rate from admission to intensive care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>activity / expression kinetic of plasma arginase</measure>
    <time_frame>during the first 7 days of ICU admission</time_frame>
    <description>3 points kinetic : admission, day 3 and day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic value of enterocyte damage</measure>
    <time_frame>28 days</time_frame>
    <description>at ICU admission and 28-day mortality rate from admission to intensive care</description>
  </secondary_outcome>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Intensive Care Units</condition>
  <condition>Infection</condition>
  <condition>Biomarkers</condition>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample at ICU admission, day 3 and day 7 biomarkers analysis: arginase activity,&#xD;
      citrulline and IFABP&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitted to the ICU for severe sepsis or septic shock&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  Patient admitted to ICU&#xD;
&#xD;
          -  Diagnosis, suspected or confirmed, of severe sepsis or septic shock&#xD;
&#xD;
          -  Expected ICU stay of at least 2 days&#xD;
&#xD;
          -  Affiliation to a social security system or recipient of a such system&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Chronic intestinal pathology&#xD;
&#xD;
          -  Chronic renal failure defined by creatinine clearance &lt;50 ml / min / 1.73m2 (CKD-EPI)&#xD;
&#xD;
          -  Severe hepatic insufficiency (Child-Pugh stage C score)&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Subject unlikely to cooperate with the study and / or weak cooperation anticipated by&#xD;
             the investigator&#xD;
&#xD;
          -  Patient within the exclusion period of another study or planned by the &quot;national file&#xD;
             of volunteers&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaël PITON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaël PITON, MD</last_name>
    <phone>381668127</phone>
    <phone_ext>+33</phone_ext>
    <email>gpiton@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucie VETTORETTI</last_name>
    <phone>381218378</phone>
    <phone_ext>+33</phone_ext>
    <email>lvettoretti@chu-besancon.fr</email>
  </overall_contact_backup>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU, sepsis, septic shok, arginase, citrulline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

